Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 7680 results

  1. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.

    Technology appraisal guidance
    Published
    23 January 2013
    View recommendations

    Sections for TA272

  2. Ranibizumab for treating diabetic macular oedema (TA274)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

    Technology appraisal guidance
    Last updated
    26 October 2023
    View recommendations

    Sections for TA274

  3. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    Evidence-based recommendations on bee venom and wasp venom (Pharmalgen) for treating bee and wasp venom allergy.

    Technology appraisal guidance
    Published
    22 February 2012
    View recommendations

    Sections for TA246

  4. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

    Technology appraisal guidance
    Published
    25 April 2012
    View recommendations

    Sections for TA254

  5. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  6. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    1 August 2013
    View recommendations

    Sections for TA215

  7. Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

    Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA216

  8. Alteplase for treating acute ischaemic stroke (TA264)

    Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.

    Technology appraisal guidance
    Published
    26 September 2012
    View recommendations

    Sections for TA264

  9. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  10. Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

    Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA266

  11. Ivabradine for treating chronic heart failure (TA267)

    Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.

    Technology appraisal guidance
    Published
    28 November 2012
    View recommendations

    Sections for TA267

  12. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

    Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA257

  13. Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

    Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA258

  14. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA235

  15. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

    Technology appraisal guidance
    Published
    26 October 2011
    View recommendations

    Sections for TA236